

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Sinopharm Tech Holdings Limited**  
**國藥科技股份有限公司**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 8156)**

**RESIGNATION OF NON-EXECUTIVE DIRECTOR AND  
APPOINTMENT OF EXECUTIVE DIRECTORS AND  
CHIEF OPERATING OFFICER**

**RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sinopharm Tech Holdings Limited (the “**Company**”) announces that Mr. CHAN Tung Mei (“**Mr. CHAN**”) has resigned as non-executive Director of the Company with effect from 17 June 2021. Mr. CHAN resigned as he would like to devote more time to his family. He has confirmed that he has no disagreement with the Board, and there are no other matters relating to his resignation that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its sincere gratitude to Mr. CHAN for his valuable contribution to the Company during his tenure.

**APPOINTMENT OF EXECUTIVE DIRECTORS AND CHIEF OPERATING OFFICER**

The Board further announces that Mr. LIAO Zhe (“**Mr. LIAO**”) has been appointed as executive Director and chief operating officer of the Company and Mr. CHEUK Ka Chun Kevin (“**Mr. CHEUK**”) has been appointed as executive Director of the Company with effect from 17 June 2021.

**Mr. LIAO Zhe**

Mr. LIAO, 34, has more than 10 years of experience in the Internet industry and 1 year of experience as an executive director of a Hong Kong listed company. From 2014 to 2017, he worked in Tencent Technology (Shenzhen) Company Limited, a wholly-owned subsidiary of

Tencent Holdings Limited (stock code: 700.HK), as the general manager of the financial institution in the WeChat Pay joint product department. From October 2017 to October 2018, he served as an executive director of Shunten International (Holdings) Limited (stock code: 932.HK). Mr. Liao holds a bachelor's degree from Beijing Normal University in Zhuhai and an advanced degree from DFI Hamburg School of Design, Germany. He was appointed as the guest speaker of the Graduate School of Industrial Engineering of the University of Hong Kong in 2015, and was the founding director of the Hong Kong Young Executives Association in 2018. Mr. Liao joined the Company in September 2019 and is currently a director of the e-commerce department of the Company. He is also the general manager of Sinopharm Health (Hainan) Technology Co., Ltd., a subsidiary of the Company. From the date of appointment, he will be fully responsible for the Company's anti-counterfeiting business, e-commerce business, Internet technology business and related businesses.

Mr. LIAO has not entered into any service contract for his duties as the executive Director with the Company. He will be entitled to receive an annual salary of HK\$1,200,000 and an annual director's fee of HK\$240,000 which were determined by the Board based on recommendation of the remuneration committee of the Company and with reference to his relevant roles, duties and responsibilities in the Company, the prevailing market conditions and the Company's performance. He is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the articles of association of the Company.

As at the date of this announcement, Mr. LIAO is interested in 2,300,000 share options of the Company. Save as disclosed above, Mr. LIAO (i) does not hold any interest in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the "SFO"); (ii) does not hold any directorship in any Hong Kong or overseas listed public companies in the last three years; and (iii) does not have any relationship with any Director, senior management or substantial or controlling shareholder(s) (as defined in the Rules Governing the Listing of Securities on GEM ("GEM") of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules")) of the Company nor does he hold any position in the Company or any of its subsidiaries.

Save as disclosed above, neither any further information is required to be disclosed pursuant to the requirements under Rule 17.50(2)(h) to (v) of the GEM Listing Rules nor any other matter relating to Mr. LIAO's appointment is needed to be brought to the attention of the shareholders of the Company.

### **Mr. CHEUK Ka Chun Kevin**

Mr. CHEUK, aged 37, holds a bachelor's degree in economics and a master's degree in applied finance from Macquarie University in Australia. Mr. CHEUK has served the Company and its subsidiaries (the "Group") for more than 12 years and is currently as a project director of the Company. He has been responsible for the investment and acquisition of various projects of the Group. He has more than 10 years of experience in the lottery industry and technological innovation and application. He has led the team to win various awards under "Interactive In-Store Marketing Solutions" and "Health Management Cloud Platform" projects in 2016 and 2017 Geneva International Invention Exhibition respectively, including a gold award in 2016 Geneva

International Invention Exhibition. He also served as a director of a subsidiary of the Company. From the date of appointment, Mr. CHEUK's management scope will be expanded to the supply management and related businesses of the lottery part of the anti-counterfeiting business.

Mr. CHEUK has not entered into any service contract for his duty as the executive Director with the Company. He will be entitled to receive an annual salary of HK\$888,000 and an annual director's fee of HK\$240,000 which were determined by the Board based on recommendation of the remuneration committee of the Company and with reference to his relevant roles, duties and responsibilities in the Company, the prevailing market conditions and the Company's performance. He is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the articles of association of the Company.

As at the date of this announcement, Mr. CHEUK is interested in 178,000 shares of the Company and 20,555,000 share options of the Company. Save as disclosed above, Mr. CHEUK (i) does not hold any interest in the shares or underlying shares of the Company within the meaning of Part XV of the SFO; (ii) does not hold any directorship in any Hong Kong or overseas listed public companies in the last three years; and (iii) does not have any relationship with any Director, senior management or substantial or controlling shareholder(s) (as defined in the GEM Listing Rules) of the Company nor does he hold any position in the Company or any of its subsidiaries.

Save as disclosed above, neither any further information is required to be disclosed pursuant to the requirements under Rule 17.50(2)(h) to (v) of the GEM Listing Rules nor any other matter relating to Mr. CHEUK's appointment is needed to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its warmest welcome to Mr. LIAO and Mr. CHEUK for their new roles in the Company.

By order of the Board  
**Sinopharm Tech Holdings Limited**  
國藥科技股份有限公司  
**CHAN Ting**  
Chairperson

Hong Kong, 17 June 2021

*As at the date of this announcement, the Board comprises Mr. CHAN Ting, Mr. LIAO Zhe and Mr. CHEUK Ka Chun Kevin as executive Directors, Madam CHEUNG Kwai Lan and Dr. CHENG Yanjie as non-executive Directors and Mr. LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. CHAU Wai Wah Fred as independent non-executive Directors.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this*

*announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the GEM website at [www.hkgem.com](http://www.hkgem.com) for a minimum period of 7 days from the date of its publication and on the website of the Company at [www.sinopharmtech.com.hk](http://www.sinopharmtech.com.hk).*